Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's biosimilar front-runner Celltrion said it will push back the anticipated launch of biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to early 2012, instead of the original plan for a launch in the second half of 2011
You may also be interested in...
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.
Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City